Member Info for cn100

If you’re asking what Trellus Health plc might sell for in an acquisition, the answer depends far more on its technology, customer contracts, intellectual property, and growth prospects than on its current share price.

A few relevant data points:

* The company’s market capitalization recently fell to roughly £0.5–0.7 million.

* Revenue remains very small, around $0.3–0.4 million annually, although growth has been significant from a low base.

* The company has continued signing commercial agreements, including relationships with major healthcare and pharmaceutical organizations.

* It has faced funding and cash-runway challenges, which can reduce negotiating leverage in a sale.

Using typical healthcare-tech acquisition ranges:

Scenario

Approximate Sale Value

Distressed asset sale

£1–5 million

Strategic buyer wants the platform/IP

£5–20 million

Buyer sees significant future commercial value

£20–50+ million

Major breakthrough in contracts or adoption before sale

Potentially higher

Given the company’s current revenue and market value, a sale in the £5–20 million range would not be unreasonable for a strategic acquisition, even though that could be many times the current market cap. Buyers often pay for technology, data, customer relationships, and talent rather than current earnings.

My interpretation of today’s Trellus announcement is that it is better than running out of cash, but it does not solve the core problem.

Today’s news is that Trellus secured a $260,000 unsecured loan from Mount Sinai Health System, which extends its cash runway to 31 July 2026.

Positives

* The company obtained funding from a credible strategic partner rather than a highly dilutive emergency equity raise.

* It buys management additional time to continue restructuring discussions and pursue strategic options.

* Mount Sinai’s willingness to lend could be viewed as a sign that key stakeholders still see value in the business and its technology.

The critical question is no longer whether Trellus can survive the next few weeks—it now has a bit more breathing room. The key question is whether management can announce one of the following before the end of July:

1. A substantial new financing package.

2. A strategic investor.

3. A sale of assets or the US subsidiary.

4. A major commercial contract that materially changes revenue expectations.

Without one of those, today’s loan looks more like a bridge to the next decision point than a turnaround.

From a market perspective, I would classify today’s update as cautiously positive operationally but not yet transformational financially. The announcement reduces immediate liquidity pressure, but investors will likely want evidence of a longer-term funding solution before becoming significantly more optimistic.

0.525p works out at about £2.25m

with 430m shares in issue.

Number of AIM securities in issue Was updated yesterday to correct up to date figure. First time since 13th march: even though date still shows 13th march on significant shareholders.

https://trellushealth.com/shareholder-information

Suspension stops the CLN's from Alumni being converted. THere would have been another 80M shares today or next week converted. All for a measely £50k. I cant imagine Mount Sinai were happy with this arrangement. There is currently 430M shares in issue so mcap is around £500k. Perhaps it was agreed the only way to stop the rot was to suspend for now until something is finalised on the funding side of things.

That’s the last part of alumni cleared. 36.5m and that trade of 22m adds up to what they took.

Can trellus now stop using them and have a positive funding rns tomorrow instead ?

A big announcement coming imo

Surely the Icahn school of medicine who is the largest shareholder here will come in with a loan of £2-£3m which will see them through for 12 months. Cancel the CLN with Alumni with immediate effect and then Trellus can continue with their work for the foreseeable??

Info on the largest shareholder from chatgtp:

The Icahn School of Medicine at Mount Sinai doesn’t have a public “market value” because it’s a nonprofit medical school, not a company traded on the stock market.

But financially, it’s very large:

* Endowment: about $866 million (2023)

* Total assets: about $4.26 billion

* Net assets: about $1.5 billion

* Annual revenue: about $4.16 billion

A big reason the school became so wealthy and well known was a $200 million donation from Carl Icahn in 2012, which is why the school was renamed.

So if you’re asking “how much is it worth,” the closest estimate would be:

* roughly $1.5 billion in net worth/assets after liabilities, or

* over $4 billion in total assets overall.

I am expecting either:

1- one of the large holders either cantor or spreader to have reduced on Friday

2 - one or more of the warrant holders will convert some off their warrants at 0.1p

3 - a placing.

I knew something wasn’t right Friday morning you can usually tell the first hour of trading what the game plan is. And adjusted position accordingly.

Step 1: Resource size

From earlier: about ~600,000 tonnes of LCE at the Zulu project owned by Premier African Minerals.

Step 2: Lithium price (very variable)

Lithium prices swing a lot:

2022 peak: ~$70,000 per tonne

2024–2025 range: roughly $10,000–$20,000 per tonne

Step 3: Rough in-ground value

Multiply:

Low case ($10k/t):

600,000 × $10,000 ≈ $6 billion

Mid case ($15k/t):

≈ $9 billion

High case ($20k/t):

≈ $12 billion

⸻

⚠️ Important reality check

That does NOT mean the company is worth $6–12 billion. The actual value is much lower because:

Mining, processing, and infrastructure cost a lot

Not all lithium can be economically extracted

Time (it takes years to produce) reduces value

Political and operational risks matter

In practice, early-stage lithium projects are often valued at 5–20% of in-ground value.

👉 So a more realistic project/company valuation might be something like:

~$300 million to $2 billion (very rough range)

Once this gets going I expect the ride will be just as good as smarter web company rise which went from 3p to 600p (200 times increase)

One could argue this could be worth £500m to £1billion. (100 to 200 times the current valuation.

0.035p for me

Last August it was valued at around £25m mcap. Now with 25b shares it’s around £5m.

Surely looks very attractive at this price now a lot of progress has been made since then?

If he can be believed….

A lot to prove here, the last placing was the killer here after promising £2m at 2p and then £3. 25m at 0.5p. Neither materialised. Only a lousy£ 0.5m at 0.15p

Needs to show something substantial very soon.

Come on Sath do the right thing and resign. This needs a reset a someone in charge that has some savvy about them !

Stark which were your sells yesterday?

Massive news….

Level 2 looks awful. 1 vs 4

Expect to drop more.

Bet it doesn’t… still watching and waiting…

Back to 1,000,000 available at 1.89p so going no where while the stock is still available.

The limits online to buy have dropped from 1,100,000 to now 375,000. Possibly the seller getting near to finishing ? Any more decent buys and an increase in volume to the buy side will be interesting.